Outstanding Care, Compassionate People, Healthier Communities



King's Mill Hospital

Mansfield Road

Sutton in Ashfield

Nottinghamshire

ngnamsnire NG17 4JL

Kingis Mill Hospital
Join today: www.sin-irin Solid
Sutton in Ashield

Nottinghamshire NG17 4JL

Tel: 01623 622515 Join today: www.sfh-tr.nhs.uk

Direct Line: 01623 672232

Our Ref: 1210

E-mail: sfh-tr.foi.requests@nhs.net

5th December 2025

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: FOI Request: Treatment of breast cancer

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.








FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) • Alpelisib (Piqray) • Elacestrant (Orserdu) • Fulvestrant (fulvestrant or Faslodex) • Inavolisib (Inaqovi) • Palbociclib (Ibrance) • Ribociclib (Kisqali) • Capivasertib (Truqap) • Talazoparib (Talzenna) • Olaparib (Lynparza)	 Abemaciclib (Verzenios) – 5 Patients Alpelisib (Piqray) – 0 Patients Elacestrant (Orserdu) – 0 Patients Fulvestrant (fulvestrant or Faslodex) – 10 Patients Inavolisib (Inaqovi) – 0 Patients Palbociclib (Ibrance) – 0 Patients Ribociclib (Kisqali) – 0 Patients Capivasertib (Truqap) – 0 Patients Talazoparib (Talzenna) – 0 Patients Olaparib (Lynparza) – 1 Patients 			
 2. How many patients received the following medicines for early breast cancer in the 3 months between 1st July 2025 to the end of September 2025? Abemaciclib (Verzenios) Ribociclib (Kisqali) Olaparib (Lynparza) 	 Abemaciclib (Verzenios) – 1 Patients Ribociclib (Kisqali) – 0 Patients Olaparib (Lynparza) – Patients 			

Home, Community, Hospital.







3. How many patients received the following medicines with curative treatment intent in the 3 months between 1st July 2025 to the end of September 2025? • Abemaciclib (Verzenios) • Ribociclib (Kisqali)	Abemaciclib (Verzenios) – 1 Patients Ribociclib (Kisqali) – 0 Patients	
 4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the 1st July 2025 to the end of September 2025? Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) 	Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Information not held in the requested format to identify drugs in combination.	
 5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the 1st July 2025 to the end of September 2025? All types of breast cancer Locally advanced or metastatic breast cancer 6. How many patients were treated in total with 	All types of breast cancer – 1 Patient Locally advanced or metastatic breast cancer – 0 Patients Pertuzumab (Perjeta) – 0 Patients	
the following products in the 3 months between	Pertuzumab with Trastuzumab (Phesgo) – 0	

Home, Community, Hospital.








1st July 2025 to the end of September 2025?	Patients		
Pertuzumab (Perjeta)	Trastuzumab (Herceptin, Herzuma, Kanjinti,		
Pertuzumab with Trastuzumab (Phesgo)	Ontruzant, Trazimera, Zercepac, trastuzumab) – 0		
Trastuzumab (Herceptin, Herzuma, Kanjinti,	Patients		
Ontruzant, Trazimera, Zercepac, trastuzumab)	Trastuzumab Deruxtecan (EnHertu) – 0 Patients		
Trastuzumab Deruxtecan (EnHertu)	Trastuzumab Emtansine (Kadcyla) – 0 Patients		
Trastuzumab Emtansine (Kadcyla)	Tucatinib (Tukysa) – 0 Patients		
Tucatinib (Tukysa)	Neratinib (Nerlynx) – 0 Patients		
Neratinib (Nerlynx)	, , ,		
7. How many patients were treated with the	Trastuzumab (Herceptin, Herzuma, Kanjinti,		
following products for a diagnosis of Breast	Ontruzant, Trazimera, Zercepac, trastuzumab) – 0		
Cancer (ICD-10 codes = C50*, D509) in the 3	Patients		
months between 1st July 2025 to the end of	Trastuzumab Deruxtecan (EnHertu) – 0 Patients		
September 2025?			
Trastuzumab (Herceptin, Herzuma, Kanjinti,			
Ontruzant, Trazimera, Zercepac, trastuzumab)			
Trastuzumab Deruxtecan (EnHertu)			
8. How many patients received the following	Pertuzumab (Perjeta) – 0 Patients		
products with curative treatment intent in the 3	Pertuzumab with Trastuzumab (Phesgo) – 0		
months between the 1st July 2025 to the end of	Patients		
September 2025?	Trastuzumab (Herceptin, Herzuma, Kanjinti,		
Pertuzumab (Perjeta)	Ontruzant, Trazimera, Zercepac, Trastuzumab) – 0		
Pertuzumab with Trastuzumab (Phesgo)	Patients		
Trastuzumab (Herceptin, Herzuma, Kanjinti,	Trastuzumab Emtansine (Kadcyla) – 0 Patients		

Home, Community, Hospital.







Ontruzant, Trazimera, Zercepac, Trastuzumab) • Trastuzumab Emtansine (Kadcyla) 9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the 1st July 2025 to the end of September 2025?	Pertuzumab (Perjeta) – 0 Patients Pertuzumab with Trastuzumab (Phesgo) – 0 Patients Trastuzumab (Herceptin, Herzuma, Kanjinti,		
 Pertuzumab (Perjeta) Pertuzumab with Trastuzumab (Phesgo) Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) Trastuzumab Emtansine (Kadcyla) 	Ontruzant, Trazimera, Zercepac, trastuzumab) – 0 Patients • Trastuzumab Emtansine (Kadcyla) – 0 Patients		
10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the 1st July 2025 to the end of September 2025? • HER2+ve Breast Cancer • HER2-low Breast Cancer	HER2+ve Breast Cancer – 0 Patients HER2-low Breast Cancer – 0 Patients		

Home, Community, Hospital.









11. How many patients were treated for the
following indications for metastatic HER2+ve
breast cancer by product, in the 3 months
between 1st July 2025 and 30th September 2025,
or latest 3-months for which data are available?
a) Following one prior anti HER2-based regimen
Trastuzumah Deruxtecan (Enhertu)

- Trastuzumab Deruxtecan (Enhertu)
- Trastuzumab Emtansine (Kadcyla)
- Trastuzumab
- b) Following one or more prior anti-HER2-based regimens
- Trastuzumab Deruxtecan (Enhertu)
- Trastuzumab Emtansine (Kadcyla)
- Trastuzumab

- Trastuzumab Deruxtecan (Enhertu) 0 Patients
- Trastuzumab Emtansine (Kadcyla) 0 Patients
- Trastuzumab b) Following one or more prior anti-HER2-based regimens - 0 Patients
- Trastuzumab Deruxtecan (Enhertu) 0 Patients
- Trastuzumab Emtansine (Kadcyla) 0 Patients
- Trastuzumab 0 Patients

Home, Community, Hospital.





Outstanding Care, Compassionate People, Healthier Communities



I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: https://ico.org.uk/your-data-matters/official-information/.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for reuse under the Open Government Licence (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.

7

Home, Community, Hospital.





